Ucb SA
F:UNC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Ucb SA
F:UNC
|
BE |
|
N
|
National Grid PLC
XMUN:NNGF
|
UK |
|
I
|
International Consolidated Airlines Group SA
XMUN:INR
|
UK |
|
S
|
Standard Chartered PLC
F:STD
|
UK |
|
A
|
Antimony Resources Corp
F:K8J0
|
CA |
|
S
|
Shams Textile Mills Ltd
KAR:STML
|
PK |
|
Fastpasscorp A/S
CSE:FASTPC
|
DK |
|
T
|
Thales SA
DUS:CSF
|
FR |
|
Repsol SA
OTC:REPYF
|
ES |
|
B
|
Bang & Olufsen A/S
F:BUOB
|
DK |
Earnings Calls
Last Earnings Call
Strong first half: UCB said total net sales rose 23% to EUR 4.1 billion and revenue rose 22% to EUR 4.3 billion, with growth driven mainly by its five growth products and solid CIMZIA performance.
BIMZELX momentum: Management raised BIMZELX peak sales potential to at least EUR 7 billion, citing broad launch progress, new superiority data in psoriatic arthritis, and expanding access.
Guidance up: UCB upgraded full-year 2026 guidance for both revenue and EBITDA, while noting second-half phasing effects from BRIVIACT LOE, prior-year gross-to-net benefits, and new BIMZELX access terms.
Pipeline expansion: The company advanced bepranemab into confirmatory Phase II, moved galvokimig into respiratory indications, and said cizutamig will enter Phase II exploratory studies in 2026.
BD active: UCB completed four acquisitions in the half, including Candid Therapeutics and Neurona, to deepen its immunology and epilepsy franchises.
Questions focused on pricing: Analysts pressed management on BIMZELX net price pressure from improved access; UCB said it is comfortable with Visible Alpha 2026 consensus and expects volume gains to build over time.